Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M7DU
|
|||
| Former ID |
DIB014742
|
|||
| Drug Name |
Radiolabeled onartuzumab
|
|||
| Synonyms |
Onartuzumab-[76Br]; Onartuzumab-[89Zr]; Bromine-76-onartuzumab; Radiolabeled onartuzumab (imaging, cancer); Zirconium-89-onartuzumab; Radiolabeled MetMab (humanized mAb, cancer), Genentech; Radiolabeled onartuzumab (imaging, cancer), Genentech; 76Br-MetMab; 76Br-labeled MetMab (humanized mAb, cancer), Genentech; 76Br-onartuzumab; 89Zr-MetMab; 89Zr-labeled MetMab (humanized mAb, PET contrast agent), Genentech; 89Zr-onartuzumab
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Company |
Genentech Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.